MedTrace Logo

The Swedish BioFINDER - Preclinical AD Study

NCT06121544 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2026-04-06

No results posted yet for this study

Summary

This research study aims to examine biomarkers of Alzheimer's disease (AD) as early as possible which could potentially be a screening tool for the general population. This observational study will take place at the Skåne University Hospital in Sweden. The study will enroll up to 600 cognitively healthy subjects aged 50 to 80 years with 3/4 having preclinical Alzheimer's disease. Recruitment and enrollment will be ongoing for 2-3 years, and subject participation will be lasting approximately 4 years. Disclosure of AD risk assessments will be an optional procedure.

Conditions

Interventions

DIAGNOSTIC_TEST

Plasma tau

Plasma levels of different p-tau and np-tau species

DIAGNOSTIC_TEST

Plasma β-Amyloid 42/40 (Aβ42/Aβ40)

Plasma levels of Aβ42/Aβ40 ratio

DIAGNOSTIC_TEST

Flutemetamol F18 Injection

Positron emission tomography (PET) imaging of amyloid-β plaques

DIAGNOSTIC_TEST

[18F]-RO6958948 Injection

PET imaging of Tau aggregates

DIAGNOSTIC_TEST

Magnetic resonance imaging (MRI)

Different MRI sequences relevant for brain imaging

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • Skane University Hospital

    lead OTHER

Principal Investigators

  • Erik Stomrud, MD, PhD · Skane University Hospital and Lund University

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06121544 on ClinicalTrials.gov